Reply to: "Prior surveillance can bias cross-sectional validation of novel HCC biomarkers: incumbent test bias" [0.03%]
对“术前监测会偏倚新型肝癌生物标志物的横断面验证：现有检测偏差”的回复
David J Taggart,Scott D Barnett,Mindie H Nguyen
David J Taggart
Johannes Hartl,Jan Philipp Weltzsch,Marcial Sebode et al.
Johannes Hartl et al.
Corticosteroid Therapy for Drug-induced Liver Injury: Mind the Gap! [0.03%]
注意！药物性肝损伤的糖皮质激素治疗仍存未知领域！
Guruprasad P Aithal,Sabine Weber,Hester Franks
Guruprasad P Aithal
Idiosyncratic drug-induced liver injury (DILI) resolves following discontinuation of the causative drug in about 80% of individuals. The injury may persist in 10%-15% beyond 6 months and about 10% die within 2 years from the time of DILI on...
OSM-STAT3 signaling facilitates Long-term expansion of Pediatric Hepatic Organoids [0.03%]
OSM-STAT3信号传导可促进儿科肝类器官的长期扩张
Yahui Li,Ying Wang,Ying Lu et al.
Yahui Li et al.
Systemic therapy of biliary tract cancer: The road to personalised strategies [0.03%]
胆道癌的系统治疗：迈向个性化策略之路
Angela Lamarca,James J Harding,Do Youn Oh
Angela Lamarca
Biliary tract cancers (BTC), including cholangiocarcinoma, gallbladder cancer, and ampullary cancer, remain poor-prognosis tumours. Chemo-immunotherapy is now established as the first-line standard of care. In parallel, precision medicine i...
Reproducibility of Biomarkers in MASLD: A Benchmark for Clinically Meaningful Change in Serially Measured Non-Invasive Tests [0.03%]
MASLD生物标志物的重复性：连续测量非侵入性检查临床有意义变化的参考标准
Tsz Yuen Au,Amanda Darekar,Vincent Wai-Sun Wong et al.
Tsz Yuen Au et al.
Background: The use of non-invasive tests NITs to monitor disease severity in metabolic-dysfunction associated steatotic liver disease (MASLD) necessitates a clear understanding of clinically meaningful changes at the pat...
Shahid A Khan,Mathew Vithayathil,Terry C F Yip et al.
Shahid A Khan et al.
During the 21st century, the global burden of primary liver cancer has continued to rise, with the absolute numbers of incident cases and deaths increasing by 59.4% and 55.8%, respectively, between 2000 and 2023. Analysis of the GBD 2023 da...
Beyond editing: delivery systems will shape the future of gene therapy for chronic liver disease [0.03%]
超越编辑：递送系统将塑造慢性肝病基因治疗的未来
Silvia Diviccaro,Jörn M Schattenberg
Silvia Diviccaro
Metabolic dysfunction profiles identify heterogeneous hepatocellular carcinoma risk in MASLD-associated advanced fibrosis [0.03%]
代谢功能紊乱谱型可识别与MASLD相关晚期肝纤维化中异质性肝细胞癌风险
Mario Romeo,Marcello Dallio,Carmine Napolitano et al.
Mario Romeo et al.
Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction [0.03%]
低剂量贝伐单抗联合阿特朱单抗可通过纠正血管免疫生态位功能障碍来增强TACE在肝癌中的疗效
Chenghao Zhao,Huzheng Yan,Zhixing Liang et al.
Chenghao Zhao et al.
Background & aims: Transarterial chemoembolization (TACE) treatment for hepatocellular carcinoma (HCC) commonly results in residual disease; however, the angiogenic features of residual tumors remain poorly defined. This ...